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Abstract  
BACKGROUND: Pulmonary embolism and deep venous thrombosis, known as venous 
thromboembolism (VTE), are associated with a high proportion of morbidity and mortality.  
AIM: Aim of this review is to emphasise current diagnostic and therapeutic modalities for VTE.  
RESULTS: No differences have been noticed in European and American guidelines in diagnostic 
approach of this disorder. Today there is enough clinical information for the use of heparin (either, 
unfractionated or low molecular) and vitamin K antagonists in the treatment of acute and chronic 
phases of VTE. Novel oral anticoagulants seem to have some advantages in the treatment of this 
disorder. Rivaroxaban has been approved widespread, for use as a single-drug approach of VTE.  
CONCLUSION: Both guidelines are almost similar and good basis for evidence-based treatment of 
this disorder. 
 
 
 
 
 
 
 
Introduction 
 
Pulmonary thromboembolism (PE) is a 
disorder of the pulmonary circulation because of the 
presence of thrombi. Thrombi are usually formed in 
the venous circulation (deep vein thrombosis or DVT). 
These two entities are known by the common term: 
venous thromboembolism.  
The importance of VTE comes from its 
association with a high proportion of morbidity and 
mortality [1]. This disorder is often asymptomatic, 
misdiagnosed, unrecognised and untreated. 
  
Diagnosis 
The diagnosis is established on the basis of 
clinical presentation and risk factors present. Clinical 
signs and symptoms are often nonspecific, for which 
everyVTE is hardly familiar. The most common 
symptoms are loss of consciousness (due to a relative 
lack of oxygen supply to the brain), dyspnea or 
tachypnea (because of respiratory decline in vital 
capacity, atelectasis and vasoconstriction), chest pain 
(RH=right heart ischemia, pleural effusion), 
hemoptysis, (alveolar hemorrhage), and high 
temperature and cough (additional infection). 
Symptoms are present with the obstruction of more 
than 50 % of pulmonary circulation. Sudden cardiac 
death occurs in obstruction of the pulmonary arteries. 
This, in turn, produces large pulmonary peripheral 
resistance, triggers right heart failure and systemic 
hypotension, while isolated segmental and 
supsegmental VTE do not initiate these dramatic 
clinical symptoms [2]. 
The clinical probability for PE is based on the 
existence of risk factors and their significance. There 
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is not a universal cutpoint for D-dimer, it is assayed 
dependent D-dimer test is used as a test to exclude 
PE.  
Doppler ultrasound of deep veins of the legs 
is a diagnostic test for the presence of VTE. 
Ventilation-perfusion lung scan is a proven diagnostic 
test for suspected PE with low sensitivity. 
 Echocardiography has a limited role in PE. 
However, it is used, where transfer for definitive 
imaging is not possible and thrombolysis is being 
considered. CT angiography (multislice) is a method 
of choice for the diagnosis of PE by direct evidence of 
a clot, breakdown charge pulmonary arterial branch. 
Pulmonary angiography by Seldinger is the gold 
standard, although is used less often. All mentioned 
diagnostic tools are part of the diagnostic algorithm for 
PE. Echocardiography is sufficient to diagnose PE in 
high-risk patients. CT angiography is completed when 
the patient is stabilised, or when it is available. 
 Differential diagnoses are noted as acute 
myocardial infarction, myocarditis or pneumothorax or 
specific conditions of right heart failure. Diagnosis of 
deep vein thrombosis is based on to the vascular 
ultrasound examinations. Vein ultrasound detects 
noncompresibiily of affected vein, loss of respiratory 
phasic signal and visualisation of thrombus [3]. 
  
 Treatment 
 Rapid initiation of treatment is most important 
even when there is a suspicion of VTE [4, 5]. 
 Acute treatment of patients with PE (without 
high risk) consists of the use of heparin 
(unfractionated or low-molecular) or fondaparinux. 
During this phase,a laboratory with blood tests is 
required, along with the values of activated 
thromboplastin or kaolin cefalin's time. Both heparins 
are known to be safe and as effective. In comparison 
with low-molecular-weight heparin, initial therapy with 
unfractionated heparin was associated with higher 
mortality and a higher rate of fatal pulmonary 
embolism in patients. The treatment continues with 
oral vitamin K anticoagulants (Acenocoumarol) in 
accordance with appropriate scheme value of INR 
(International proportion value to be between 2 and 3). 
Alternatively, treatment with Dabigatran or 
Rivaroxaban is equivalent in the long term phase of 
treatment.  
High-risk PE is an indication, however,for 
quick treatment with fibrinolytic therapy. 
Novel oral anticoagulants seem to have some 
advantages in the treatment of this disorder. Current 
Cohen’s meta-analysis indicates that the NOACs have 
a clinical benefit over conventional therapy while 
compared to their relative differences in bleeding 
profile. 
Rivaroxaban has been approved for 
widespread use as a single-drug approach of VTE. 
This drug is not inferior in the treatment of PE (not 
high risk) in its acute phase. In patients who had acute 
symptomatic proximal DVT, without symptomatic PE, 
Rivaroxaban showed: Non-inferiority for efficacy when 
compared with treatment regimen LMWH/VKA, same 
safety outcomes (irrespective of age, gender and 
body weight, renal function or presence of cancer) 
and no evidence of hepatic toxicity. 
But, until today, there is no statement on 
which NOACs might be more beneficial (or have 
greater evidence) versus standard coagulation in the 
acute phase of VTE [6]. Rivaroxaban is approved as a 
medication for all indications in the treatment and 
prevention of venous thromboembolism, the 
prevention of VTE in patients undergoing major 
orthopaedic surgery, and for nonvalvular atrial 
fibrillation in order to prevent systemic peripheral 
embolism, including stroke.These recommendations 
are contained in the current guidelines of the 
European Society of Cardiology and the American 
Lung Physicians' Association. These noted here are 
based on EINSTEIN studies’ results. 
A comparison of VKA antagonist, NOAC and 
direct thrombin inhibitors is given in Table 1. 
Table 1: Characteristics of VKA antagonist, NOAC and direct 
thrombin inhibitors [7] 
 
 
VKA have some disadvantages as narrow 
therapeutic window, regular coagulation monitoring 
and dose adjustment, lack of staying in therapeutic 
range (INR 2-3) for all pts and consequent increase in 
the risk of thromboembolic events or side effects – 
bleeding, significant inter - and intra - individual 
variations in the response due to: numerous 
interactions with food and medicine and complex 
pharmacokinetics and pharmacodynamics. 
Because of the foreseeable pharmacology 
and broad therapeutic window, Rivaroxaban is the 
drug of choice and replaced other anticoagulants.  
The minimum duration of anticoagulation for 
VTE is 3 months (m); Till today, there is no evidence 
to suggest 6 m is more effective than 3 m. Duration of 
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treatment of patients with transient risk factor is up to 
6 months. Long-term anticoagulant therapy is 
common in patients without apparent risk factors and 
those with proven thrombophilia (hypercoagulability). 
It is aimed for prevention of fatal and non- fatal 
recurrent VTE events taking into account the risk of 
bleeding. 
Due to CHEST Guidelines, for VTE long-term 
anticoagulant therapy, rivaroxaban and another 
NOAC is suggested one, (Grade 2B), over vitamin K 
antagonist (VKA) therapy, and VKA therapy instead of 
low-molecular-weight heparin (LMWH; Grade 2C). For 
VTE and cancer, we suggest LMWH over VKA (Grade 
2B), Rivaroxaban and other NOACS (Grade 2C) [8]. 
European Guidelines on pulmonary embolism is an 
evidence-based document for VTE with equivalent 
evidence for its treatment. A Macedonian 
recommendation for treatment of PE is an evidence-
based document, coming from European Guideline. 
Prognosis of venous thromboembolism 
depends on of disease severity, aetiology and timing 
from diagnosis to initiation of therapy. VTE pts with 
appropriate clot lysis have a better survival rate. 
Rivaroxaban, as a novel anticoagulant is approved for 
the acute and chronic phase of treatment of VTE. 
Patients’ adherence according to CHEST guidelines 
was high and resulted in low rates of recurrent VTE 
and bleeding. The risk of VTE recurrence after 
discontinuation of therapy is primarily determined by 
two factors: whether the acute episode was treated 
effectively and internal risks of a new episode of VTE. 
All patients with present pulmonary hypertension have 
impaired quality of life and worse survival [9]. 
In conclusion, pulmonary embolism and deep 
venous thrombosis, also known as venous 
thromboembolism (VTE), are associated with the high 
proportion of morbidity and mortality. Current 
guidelines propose Computer Tomography 
angiography, Echocardiography, Venous ultrasound 
and D-dimmers test for diagnosis of VTE.  
Early initiation of treatment of VTE is a crucial 
one. Rivaroxaban and other novel oral anticoagulant 
are effective in a treatment of venous 
thromboembolism, as traditional anticoagulants are. In 
that way, both guidelines are almost similar and good 
basis for evidence-based treatment of this disorder. 
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